CELLINK has acquired Visikol
CELLINK has acquired Visikol Corp., an American contract research services company offering leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharma and biotech companies. CELLINK has acquired all outstanding shares in Visikol for a purchase price of $7.5 million on a cash- and debt-free basis under the assumption that the working capital at closing equals the normalized working capital at closing of which approximately $2.5 million will be paid in 57,911 newly issued shares of series B in CELLINK at a price of SEK 357.60 per share (Consideration Shares) and the remainder in cash.
